Last updated on November 2017

Allergan Migraine MD-01


Brief description of study

Allergan Migraine MD-01

Detailed Study Description

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine.

Clinical Study Identifier: TX15429

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Columbus Regional Research Institute

Columbus Regional Research Institute
Columbus, GA USA
  Connect »